TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Open Label Comparative Trial of Dinoprostone Plus or Minus Oxytocin Versus Oxytocin Alone in Cervical Ripening for Labor Induction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Singleton pregnancy~* Gestational age ≥ 38 weeks~* Fetal cephalic presentation~* Bishop score \< 6~Exclusion Criteria:~* No uterine scar (no previous delivery by caesarean section)~* No more than 3 previous vaginal births~* No condition that disallows use of prostaglandins for induction of labor~* Premature rupture of the membranes~* Oligohydramnios

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Oestradiol Pre-treatment in an Ultrashort Flare GnRH Agonist/GnRH Antagonist Protocol in Poor Responders Undergoing IVF

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with poor or no response in previous COH for IVF cycles~* Patients with AMH \< 1 and/or FSH \>12~* Poor quality of embryos in previous cycles~* Age of patients up to 44 years~Exclusion Criteria:~* Patients with normal ovarian reserve~* Patients with sonographically detected hydrosalpinges~* Presence of intramural fibroid distorting the endometrial cavity or submucous myoma or Asherman's syndrome~* Women with thrombofilia disorders

- Gender: FEMALE
- Minimum Age: 25 Years
- Maximum Age: 44 Years
- Healthy Volunteers: f

Study Arms:
- Oestradiol and ultrashort GnRH agonist/antagonist protocol (Type: EXPERIMENTAL): Women will begin pretreatment with 4 mg/day of 17 β-estradiol before the combination of GnRH ultashort agonist and antagonist protocol
- GnRH agonist or antagonist protocol. (Type: ACTIVE_COMPARATOR): Women will undergo either a conventional short or long GnRH agonist or an antagonist protocol during COH for IVF

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Intracranial Aneurysms and Cognitive Function

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with un-ruptured aneurysms in the anterior communicating artery and the middle cerebral artery.~* A subgroup of patients suffering aneurismal subarachnoid hemorrhage.~Exclusion Criteria:~* History of earlier cerebrovascular, psychiatric or neurological disease.~* Age older than 75 years~* Lack of fluency in Norwegian~* Alcohol or Substance abuse~* Aphasia~* Substantial vision or hearing deficits

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Subarachnoid hemorrhage (Type: None): A group of patients suffering aneurismal subarachnoid hemorrhage will participate in a fMRI study.
- Prophylactic surgical treatment of un-ruptured aneurysms (Type: None): A retrospective follow-up study of patients who have received prophylactic surgical treatment of un-ruptured aneurysms
- Conservative treatment (Type: None): A retrospective follow-up of patients receiving conservative (life stile etc.) treatment of un-ruptured aneurysms.
- Control group of healthy subjects (Type: None): Control group of healthy subjects

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Effect of High-Intensity Gait Training Using a Treadmill on Locomotion Recovery in Traumatic Brain Injury Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Medical and treadmill screening clearance to participate in this study~* Persons with mild, moderate, or severe Traumatic Brain Injury at onset (first time or repeats)~* 18-65 years old persons who are able to ambulate on treadmill with or without assistive devices and with or without need for bodyweight-support harness system~* Ability to communicate with investigators to follow protocol instructions and respond appropriately~* Patients who have decision-making capacity and are able to consent for themselves~Exclusion Criteria:~* Unstable orthopedic conditions, for example, unstable craniectomies or weight-bearing restrictions.~* Unstable cardiac conditions including, unstable angina, unstable cardiac dysrhythmias, myocardial ischemia or hypertension at rest (systolic BP \> 140mm Hg and diastolic BP \>90 mm Hg, or if over this range, then a physician must clear patient for participation)~* Acute systemic infection accompanied by fever, body aches or swollen lymph glands.~* Hospitalization for acute cardiac, pulmonary or metabolic conditions in the past 3 months.~* Any other physical or mental restrictions preventing participation in the research protocol.~* Women who are pregnant are being excluded as this is considered a high risk study. They will be asked via verbal questioning via the following statements, Are you currently pregnant? or Are you planning to become pregnant?.~* Non-English Speakers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- High-Intensity Treadmill Gait Training (HIGT) (Type: EXPERIMENTAL): High-intensity walking physical therapy with some low intensity therapy.
- Low Intensity Physical Therapy (Type: ACTIVE_COMPARATOR): Low-intensity gait activities, exercises (such as lower extremity strength training with or without weights or electrical stimulation, sit to stands from a chair, mat exercises for upper/lower extremities and core strength, etc.), stretches, balance training activities, and other therapeutic activities (such as transfers, bed mobility training, etc.).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Second Enhanced Control of Hypertension and Thrombectomy Stroke Study (ENCHANTED2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Age ≥18 years; Diagnosis of AIS with LVO confirmed by brain imaging; To receive MT \<24 hours after AIS onset according to local guidelines; Successful recanalization (TICI score ≥2b) after MT; Sustained systolic BP ≥140 mmHg (defined as 2 successive readings \<10 mins) within 3 hours after recanalization; Provide written informed consent (or approved surrogate).~Exclusion Criteria:~Unlikely to potentially benefit from therapy (e.g. advanced dementia) or very high likelihood of death within 24 hours post-MT, judged by responsible treating clinician; Other medical illness that interferes with outcome assessments and follow-up (e.g. known significant pre-stroke disability (mRS scores 3-5), advance cancer and renal failure); Definite indication/contraindication to different intensities of BP lowering treatment; Specific contraindications to any of the BP agents to be used (eg, patients who are hypersensitive (allergic) to any of the ingredients); Patients with aortic isthmus stenosis and arteriovenous shunt (exception: patients with haemodynamically inactive dialysis shunt); Women who are lactating; Currently participating in another trial which would interfere with outcome assessments.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention group (Type: EXPERIMENTAL): Achieving SBP level of \<120 mmHg within 1 hour after randomisation, and maintaining this level at least 72 hours.
- Control group (Type: NO_INTERVENTION): Maintaining SBP 140-180mmHg, and BP lowering treatment can be given only when BP level ≥150 mmHg in order to achieve the target of ≥140 mmHg, and maintaining this level at least 72 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of a Novel Malathion Formulation in Infants and Toddlers With Head Lice

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed active head lice infestation~* Parent or guardian must be able to apply treatment~Exclusion Criteria:~* Allergy to pediculicides or hair care products~* Scalp conditions other than head lice~* Previous head lice treatment within the past 4 weeks~* Current antibiotic treatment

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 24 Months
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): MALG

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Preventive aBlation of vEntricular tachycaRdia in Patients With myocardiaL INfarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. History of remote myocardial infarction~2. Left ventricular ejection fraction ≥ 30 to ≤ 50 % as estimated by cardiac MRI, 3D-echocardiography or via ventriculography within 30 days before enrollment~3. Documentation of sustained ventricular tachycardia (VT) by any kind of Electrocardiography (ECG) including 12 lead ECG, holter ECG, rhythm strip, event monitoring, event recorder or pacemaker within 30 days before enrollment~4. Implantable cardioverter-defibrillator (ICD) indication for secondary prevention~5. Patients who are planned to be implanted with BIOTRONIK ICDs (single, dual, triple chamber or DX device)~6. Patient has provided written informed consent~7. Patient accepts activation of Home Monitoring®~Exclusion Criteria:~1. Age \< 18 years or \> 80 years~2. Known arterial or venous thrombosis~3. Class IV New York Heart Association (NYHA) heart failure~4. Valvular heart disease or mechanical heart valve precluding access to the left ventricle~5. Acute myocardial reinfarction or acute coronary syndrome~6. Cardiac surgery involving cardiotomy within the past 2 months~7. Patients requiring chronic renal dialysis~8. Thrombocytopenia or coagulopathy~9. Incessant VT or electrical storm~10. Bundle branch reentry tachycardia as the presenting VT~11. Pre-existing implantable cardioverter-defibrillator (ICD)~12. Pregnancy or breast feeding women~13. Acute illness or active systemic infection~14. Other disease process likely to limit survival to less than 12 months~15. Significant medical problem that in the opinion of the principal investigator would preclude enrollment in the study~16. Unwillingness to participate or lack of availability for follow-up~17. Participation in another interventional clinical investigation during the course of the study, i.e. the participation in a non-interventional clinical investigation is allowed.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Group 1 (TG1) (Type: EXPERIMENTAL): Prophylactic VT ablation prior to ICD implantation
- Treatment Group 2 (TG2) (Type: OTHER): ICD implantation and best medical care until the third appropriate ICD shock occurs and catheter ablation thereafter

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Topical Use of Vancomycin in Reducing Sternal Wound Infection in Cardiac Surgery (SWI Trial)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Able to sign Informed Consent and Release of Medical Information Form~* Age ≥ 18 years~* Undergoing cardiac surgery with complete sternotomy (including re-operations)~Exclusion Criteria:~* Evidence of active infection (any culture positive or blood positive infection)~* Undergoing organ transplantation~* Patients with known hypersensitivity to vancomycin~* Pregnant or nursing women~* Mental impairment or other conditions that may not allow participant to understand the nature, significance, and scope of study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vancomycin (Type: EXPERIMENTAL): During open heart surgery, patients will have a 4 x 8 inch piece of sterile gauze covering each side of the divided sternum. The gauze will be soaked in the following solution: 5 g vancomycin dissolved in 50 mL sterile water
- Control (Type: PLACEBO_COMPARATOR): During open heart surgery, patients will have a 4 x 8 inch piece of sterile gauze covering each side of the divided sternum. The gauze will be soaked in 50 mL sterile water. No Vancomycin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Coenzyme Q10 in the Treatment of Statin-Associated Myalgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who are taking statins and develop unexplained, persistent myalgia with a normal plasma creatinine kinase level~Exclusion Criteria:~* Women of childbearing potential~* Patients currently taking coenzyme Q10 (or have taken in the previous 30 days)~* Patients receiving concomitant niacin, fibric acid derivatives, bile acid sequestrants, or other drugs that effect cholesterol levels or interact with statins~* Patients with a history of alcoholism or malnutrition~* Patients who have had acute coronary syndrome or muscle trauma in the prior 7 days~* Patients with a history of chronic muscle/joint pain, fibromyalgia, or degenerative disk disease.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Aqualief® in Patients With Xerostomia as Consequence of Radiotherapy for Head and Neck Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female which are 18 years of age or older~* Patients willing and able to give signed informed consent and, in the opinion of the Investigator, to comply with the protocol tests and procedures~* Subjects presenting:hyposalivation of grade 2 or greater (according to CTCAE scale vers. 4) and an objective, unstimulated salivary flow between 0.1 and 0.25 ml/min following radiation or radiation + systemic therapies with curative intent (definitive or postoperative), for tumors located in the head / neck region, completed from at least 6 months and free from cancer disease~* Absence of infections in the oral cavity~* Absence of antibiotics and antifungal treatments or any odontoiatric procedure in the 10 days before each treatment phase of the study.~Exclusion Criteria:~* Contraindications in administration of carnosine and hibiscus~* Known hypersensitivity to the components present in the product.~* Subjects taking products or medications to reduce symptoms of salivary gland hypofunction (Pilocarpine etc.)~* Patients with other underlying conditions that can cause xerostomia.~* Use of experimental drugs within 30 days prior to enrollment or during the study.~* Presence of clinical conditions that may interfere with the study evaluations.~* Pregnant or lactating women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aqualief® tablets (Type: EXPERIMENTAL): oral mucoadesive tablets
- Placebo tablets (Type: PLACEBO_COMPARATOR): oral mucoadesive tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: OrthoPulse Gen 2 Initial Device Evaluation and Assessment of Clinical Effectiveness (CA)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Patient must be 19 years of age or older~* Likely to be compliant to OrthoPulse use, aligner wear, and Dental Monitoring scanning~* Have a compatible iOS or Android device and are willing to download the OrthoPulse and Dental Monitoring apps for frequent automatic syncing of data~Exclusion Criteria:~* Patient is currently enrolled in another clinical study~* Crowding or rotations of bilateral bicuspids that would prevent or interfere with intrusion~* Periodontally involved teeth, acute oral infection or periodontal disease~* Patient has active/untreated caries~* Use of bisphosphonates at any time~* Use of drugs that may cause photosensitivity~* History of photosensitivity~* Epilepsy~* Pregnant or planning pregnancy during the study.~* Patient plans to relocate over the treatment period

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Intervention 1 (Type: EXPERIMENTAL): Side one: No treatment Side two: OrthoPulse Gen 2 (2RP) for one minute
- Intervention 2 (Type: EXPERIMENTAL): Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (2RP) for one minute
- Intervention 3 (Type: EXPERIMENTAL): Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (2RP) for 5 minutes
- Intervention 4 (Type: EXPERIMENTAL): Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (2RCW) for five minutes
- Intervention 5 (Type: EXPERIMENTAL): Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RB 2RL) for one minute
- Intervention 6 (Type: EXPERIMENTAL): Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RB 2RL) for five minutes
- Intervention 7 (Type: EXPERIMENTAL): Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RB 2RL) for one minute
- Intervention 8 (Type: EXPERIMENTAL): Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RB 2RL) for five minutes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Secondary Versus Tertiary Wound Closure in High Risk Gynecologic Abdominal Surgical Incisions

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with high risk class II, class III, class IV abdominal wounds~* Undergoing laparotomy for gynecologic related disorders~* Patients undergoing laparotomy for both benign and malignant diagnoses will be included in this study~Exclusion Criteria:~* Pregnancy~* Allergy to triclosan~* Patients undergoing HIPEC

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Tertiary Wound Closure (Type: EXPERIMENTAL): In the alternative tertiary wound closure, the wound will be partially closed rather than being left open. Sutures in the skin will be placed but not closed. A vacuum assisted closure device will be placed over the wound to help healing. After 4-7 days, the vacuum device will be removed, and the participant's doctor will close the wound.
- Historical Wound Closure (Type: ACTIVE_COMPARATOR): The standard approach to your wound would be to leave it partially open and let it heal over a period of 3-6 months (secondary closure).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Patient-controlled Intravenous Analgesia With Remifentanil Infusion for Labour

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* Term pregnancy in labour with singleton fetus in cephalic presentation~* Patients requesting systemic analgesia~* Patients with contraindication for regional anesthesia without fetal compromise (coagulopathy, thrombocytopenia, refusal, etc.)~Exclusion Criteria:~* Refusal to sign written informed consent~* Inability to communicate in English~* Opioid dependence or addiction~* Patients on Methadone~* Allergy or hypersensitivity to remifentanil~* Fetal heart rate abnormalities~* Fetal congenital anomalies

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Continuous infusion (Type: ACTIVE_COMPARATOR): Remifentanil administered by continuous IV infusion, with stepwise increase in infusion rates and placebo demand bolus of normal saline.
- Demand Bolus (Type: ACTIVE_COMPARATOR): Demand bolus of remifentanil with stepwise increase in bolus dose and placebo continuous infusion of normal saline.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues